Simon Property Group Inc vs Twist Bioscience Corp — how do they compare? Simon Property Group Inc trades at $206.11 (market cap $68.56B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Simon Property Group Inc is far larger — about 8.1× Twist Bioscience Corp's market cap, and Simon Property Group Inc pays a 4.2% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| SPG | TWST | |
|---|---|---|
Market Cap | $68.56B | $8.42B |
Sector | Real Estate | Health |
52-Week High | $236.70 | $153.10 |
52-Week Low | $173.35 | $24.16 |
Enterprise Value | $97.00B | $8.35B |
Dividend Yield | 4.2% | — |
Signals from Pluang's Aura AI — not financial advice
SPG trades at $211.88, up 1.17% daily, with a bearish technical signal but strong fundamentals including a P/E of 14.95, robust net income margin of 66.57%, and recent Q2 2026 FFO beat. The company raised $800 million in senior notes (PRNewsWire, 2026-09-09) and launched Simon Media Network to monetize mall traffic (PRNewsWire, 2026-08-27), enhancing growth prospects despite a Q2 EPS miss.
Outlook is mixed: analyst consensus targets $231.82 with 42% buy ratings, but risks include high debt ($24.21B long-term) and bearish technicals. Opportunities lie in dividend yields and media initiatives, while headwinds involve retail real estate volatility and interest rate sensitivity.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Trailing returns across standard periods
Latest headlines on both assets
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →